This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n19http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F10%3A00003096%21RIV12-MSM-11120___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F10%3A00003096%21RIV12-MSM-11120___
rdf:type
skos:Concept n14:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1097/JTO.0b013e3181f1c8de
dcterms:description
Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK. Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations. METHODS: The %22EGFR testing in NSCLC: from biology to clinical practice%22 International Association for the Study of Lung Cancer-European Thoracic Oncology Platform multidisciplinary workshop aimed at facilitating the implementation of EGFR mutation testing. Recommendations for high-quality EGFR muta Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK. Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations. METHODS: The %22EGFR testing in NSCLC: from biology to clinical practice%22 International Association for the Study of Lung Cancer-European Thoracic Oncology Platform multidisciplinary workshop aimed at facilitating the implementation of EGFR mutation testing. Recommendations for high-quality EGFR muta
dcterms:title
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
skos:prefLabel
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
skos:notation
RIV/00216208:11120/10:00003096!RIV12-MSM-11120___
n3:aktivita
n15:N
n3:aktivity
N
n3:cisloPeriodika
10
n3:dodaniDat
n8:2012
n3:domaciTvurceVysledku
n19:7693028
n3:druhVysledku
n18:J
n3:duvernostUdaju
n5:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
251872
n3:idVysledku
RIV/00216208:11120/10:00003096
n3:jazykVysledku
n13:eng
n3:klicovaSlova
Epidermal growth factor receptor; EGFR mutation; EGFR testing recommendations; Gefitinib; Erlotinib; Non-small cell lung cancer; Tyrosine kinase inhibitors
n3:klicoveSlovo
n4:Tyrosine%20kinase%20inhibitors n4:Epidermal%20growth%20factor%20receptor n4:EGFR%20testing%20recommendations n4:Erlotinib n4:Non-small%20cell%20lung%20cancer n4:Gefitinib n4:EGFR%20mutation
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[C734E07B8E08]
n3:nazevZdroje
Journal of Thoracic Oncology
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
20
n3:rokUplatneniVysledku
n8:2010
n3:svazekPeriodika
5
n3:tvurceVysledku
Zatloukal, Petr Pirker, R.
s:issn
1556-0864
s:numberOfPages
8
n16:doi
10.1097/JTO.0b013e3181f1c8de
n17:organizacniJednotka
11120